PTEN-opathies: from biological insights to evidence-based precision medicine
Lamis Yehia,1 Joanne Ngeow,1,2,3,4 and Charis Eng1,5,6,7
1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
2Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
3Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore.
4Oncology Academic Program, Duke-NUS Graduate Medical School, Singapore.
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
6Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
7Germline High Risk Cancer Focus Group, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Address correspondence to: Charis Eng, Cleveland Clinic Genomic Medicine Institute, 9500 Euclid Avenue NE50, Cleveland, Ohio 44195, USA. Phone: 216.444.3440; Email: engc@ccf.org.
Find articles by
Yehia, L.
in:
JCI
|
PubMed
|
Google Scholar
|
1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
2Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
3Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore.
4Oncology Academic Program, Duke-NUS Graduate Medical School, Singapore.
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
6Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
7Germline High Risk Cancer Focus Group, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Address correspondence to: Charis Eng, Cleveland Clinic Genomic Medicine Institute, 9500 Euclid Avenue NE50, Cleveland, Ohio 44195, USA. Phone: 216.444.3440; Email: engc@ccf.org.
Find articles by Ngeow, J. in: JCI | PubMed | Google Scholar
1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
2Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
3Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore.
4Oncology Academic Program, Duke-NUS Graduate Medical School, Singapore.
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
6Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
7Germline High Risk Cancer Focus Group, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Address correspondence to: Charis Eng, Cleveland Clinic Genomic Medicine Institute, 9500 Euclid Avenue NE50, Cleveland, Ohio 44195, USA. Phone: 216.444.3440; Email: engc@ccf.org.
Find articles by
Eng, C.
in:
JCI
|
PubMed
|
Google Scholar
|
First published January 7, 2019 - More info
J Clin Invest. 2019;129(2):452–464. https://doi.org/10.1172/JCI121277.
Copyright © 2019, American Society for Clinical Investigation
The tumor suppressor phosphatase and tensin homolog (PTEN) classically counteracts the PI3K/AKT/mTOR signaling cascade. Germline pathogenic PTEN mutations cause PTEN hamartoma tumor syndrome (PHTS), featuring various benign and malignant tumors, as well as neurodevelopmental disorders such as autism spectrum disorder. Germline and somatic mosaic mutations in genes encoding components of the PI3K/AKT/mTOR pathway downstream of PTEN predispose to syndromes with partially overlapping clinical features, termed the “PTEN-opathies.” Experimental models of PTEN pathway disruption uncover the molecular and cellular processes influencing clinical phenotypic manifestations. Such insights not only teach us about biological mechanisms in states of health and disease, but also enable more accurate gene-informed cancer risk assessment, medical management, and targeted therapeutics. Hence, the PTEN-opathies serve as a prototype for bedside to bench, and back to the bedside, practice of evidence-based precision medicine.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)